Clinical Trial

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell transplant.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-05-06; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT06973668
Lead Sponsor M.D. Anderson Cancer Center
Conditions AML
Enrollment 80 participants
Start Date 2025-07-22
Primary Completion 2028-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-20